Forum Topic News
  • Conversation: Advancing Clinical Trials Endeavoring to Improve Odds Against Pancreatic Cancer

    • November 28, 2018 2:11 PM GMT
    • Advancing Clinical Trials Endeavoring to Improve Odds Against Pancreatic Cancer

      Moleculin Biotech, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that data from an independent test in animal models confirmed, as previously believed, that its immuno-stimulating STAT3 inhibitor achieves disproportionately high accumulation in the pancreas.
      "Our own sponsored research suggested that WP1732 might be an ideal candidate for treating pancreatic cancer," commented Dr. Donald Picker, Moleculin's Chief Science Officer. "Now, we have independent testing with radiolabeled drug confirming this in animal models. The propensity for such enhanced pancreatic distribution could be highly beneficial for a new pancreatic cancer drug."
      Read more: https://prn.to/2ra1tYL

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč